<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lymphoma: Diagnosis and Treatment</title>
</head>
<body>
    <div class="font-sans antialiased bg-dark-bg text-dark-text p-6 md:p-12">
      <div class="relative min-h-screen w-full flex flex-col items-center justify-center overflow-hidden">
        <div class="hero-background absolute inset-0 -z-10"></div>

        <header class="relative z-10 w-full max-w-6xl mx-auto text-center mb-16 px-4">
          <h1 class="text-4xl md:text-6xl font-display font-bold mb-4 gradient-text animate-fade-in-up">
            Lymphoma: Diagnosis and Treatment
          </h1>
          <p class="text-lg md:text-xl text-dark-secondary-text animate-fade-in-up">
            An In-depth Overview of Hematologic Malignancies
          </p>
        </header>

        <main class="relative z-10 w-full max-w-6xl mx-auto space-y-16">
          <section class="bg-dark-card-bg rounded-2xl p-8 md:p-12 shadow-xl card-hover-effect">
            <h2 class="font-display text-3xl md:text-4xl font-bold mb-6 text-primary-gradient-start">
              Definition and Epidemiology
            </h2>
            <p class="mb-6 text-dark-secondary-text">
              Lymphoma is a group of lymphoid neoplasms arising from the malignant
              transformation of lymphocytes (B-cells, T-cells, or NK-cells).
              It is broadly classified into Hodgkin Lymphoma (HL) and
              Non-Hodgkin Lymphoma (NHL).
            </p>
            <div class="grid grid-cols-1 md:grid-cols-2 gap-8">
              <div>
                <h3 class="text-xl font-bold mb-3 text-primary-gradient-start">
                  Hodgkin Lymphoma (HL)
                </h3>
                <ul class="list-disc list-inside space-y-2 text-dark-secondary-text pl-4">
                  <li>Characterized by Reed-Sternberg cells.</li>
                  <li>Accounts for ~10% of all lymphomas.</li>
                  <li>Incidence peaks in young adults (15–35) and adults over 55.</li>
                  <li>Overall incidence: ~2.5 per 100,000 person-years.</li>
                </ul>
              </div>
              <div>
                <h3 class="text-xl font-bold mb-3 text-accent-gradient-end">
                  Non-Hodgkin Lymphoma (NHL)
                </h3>
                <ul class="list-disc list-inside space-y-2 text-dark-secondary-text pl-4">
                  <li>More diverse group, ~90% of lymphomas.</li>
                  <li>Arises from B-cells (~85%), T-cells (~15%), or NK-cells.</li>
                  <li>Incidence increases with age (median diagnosis ~67 years).</li>
                  <li>Overall incidence: ~19.3 per 100,000 person-years.</li>
                  <li>Common subtypes: DLBCL (aggressive), FL (indolent).</li>
                </ul>
              </div>
            </div>
          </section>

          <section class="bg-dark-card-bg rounded-2xl p-8 md:p-12 shadow-xl card-hover-effect">
            <h2 class="font-display text-3xl md:text-4xl font-bold mb-6 text-primary-gradient-start">
              Pathophysiology
            </h2>
            <p class="mb-6 text-dark-secondary-text">
              Lymphomas arise from acquired genetic mutations disrupting normal
              lymphocyte development, leading to uncontrolled growth.
              Triggers include viral infections (EBV, HTLV-1, HIV),
              immunodeficiency, autoimmune diseases, environmental exposures,
              and genetic predispositions.
            </p>
            <div class="grid grid-cols-1 lg:grid-cols-2 gap-8">
              <div>
                <h3 class="text-xl font-bold mb-3 text-primary-gradient-start">
                  Hodgkin Lymphoma (HL)
                </h3>
                <p class="text-dark-secondary-text">
                  Malignant cells are a small fraction of the tumor mass;
                  majority are reactive inflammatory cells. Genetic aberrations
                  often involve NF-κB signaling activation.
                </p>
              </div>
              <div>
                <h3 class="text-xl font-bold mb-3 text-accent-gradient-end">
                  Non-Hodgkin Lymphoma (NHL)
                </h3>
                <p class="text-dark-secondary-text">
                  Diverse genetic alterations including chromosomal
                  translocations (t(14;18), MYC, BCL6),
                  BCL2 overexpression, and cyclin D1 activation in MCL.
                </p>
              </div>
            </div>
          </section>
        </main>
      </div>
      <style>
        .hero-background::before {
          content: '';
          position: absolute;
          inset: 0;
          background: linear-gradient(
            135deg,
            rgba(59, 130, 246, 0.1) 0%,
            rgba(139, 92, 246, 0.1) 50%,
            rgba(236, 72, 153, 0.1) 100%
          );
          filter: blur(120px);
          opacity: 0.7;
        }

        .gradient-text {
          background: linear-gradient(90deg, #3b82f6, #8b5cf6, #ec4899);
          -webkit-background-clip: text;
          -webkit-text-fill-color: transparent;
        }

        .card-hover-effect {
          transition: transform 0.3s ease-in-out, box-shadow 0.3s ease-in-out;
        }

        .card-hover-effect:hover {
          transform: translateY(-8px);
          box-shadow: 0 20px 40px rgba(0,0,0,0.2),
                      0 10px 20px rgba(0,0,0,0.1);
        }

        @keyframes scaleUp {
          0% { transform: scale(0.95); opacity: 0.9; }
          100% { transform: scale(1); opacity: 1; }
        }

        .animate-scale-up {
          animation: scaleUp 0.5s ease-out forwards;
        }

        @keyframes fadeInUp {
          0% { opacity: 0; transform: translateY(20px); }
          100% { opacity: 1; transform: translateY(0); }
        }

        .animate-fade-in-up {
          animation: fadeInUp 0.8s ease-out forwards;
        }
      </style>
    </div>
</body>
</html>
